Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
<i>Background and Objectives</i>: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but their use is associated with a spectrum of immune-related adverse events (irAEs), including endocrine disorders. This study aims to investigate the incidence, timing, treatment m...
Saved in:
Main Authors: | Meriç Dökmetaş, Harun Muğlu, Erkan Özcan, Buket Bayram Kuvvet, Kaan Helvacı, Ender Kalacı, Seda Kahraman, Musa Barış Aykan, İrfan Çiçin, Fatih Selçukbiricik, Ömer Fatih Ölmez, Ahmet Bilici |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/61/1/123 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
by: Ichiro Yamauchi, et al.
Published: (2023-10-01) -
Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01) -
Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning
by: Shuxian Pan, et al.
Published: (2025-01-01) -
Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages
by: Yuan Li, et al.
Published: (2024-12-01) -
Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)